Ritchlin Lab
Pathologic Bone Resorption and New Bone Formation in Inflammatory Arthritis
Bone remodeling is a dynamic and complex process finely orchestrated by cell interactions among bone-degrading osteoclasts, bone-synthesizing osteoblastosteoblasts, T cells, B cells, and natural killer cells. An imbalance between osteoclast and osteoblast activity results in skeletal and joint diseases including osteoporosis, arthritis, and non-union bone repair. These diseases impact the quality of life of patients.
Publications
View All Publications- Guselkumab Efficacy in Biologic-Naïve Participants with Psoriatic Arthritis and Severe Disease Activity: Post Hoc Analysis of a Phase 3 Study.; Rheumatology and therapy. 2025 Jul 21.
- Corrigendum to Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study Ann Rheum Dis. 2023;82:1404-1414.; Annals of the rheumatic diseases. 2025 Jun 18.
- New Insights into the Pathogenesis of Psoriatic Arthritis.; Rheumatic diseases clinics of North America; Vol 51(3), pp. 397-415. 2025 Jun 11.
- Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies.; Rheumatology and therapy. 2025 May 10.
Affiliations
News
May 23, 2025
AIR Research Presented at the 2025 AAI Meeting
May 23, 2025
Dr. Javier Rangel-Moreno Lecturer at the 2025 Course of Biomedicine and Immunology
January 15, 2025
ROChester Stimulating Access to Research during Residency (ROC StARR) Health and Immune Function Across the Lifespan to Begin July 1st
January 6, 2025
Jennifer Anolik Named Chief of Allergy, Immunology and Rheumatology Division
December 13, 2024
Ilana Abeles Receives Clinical Trial Investigator Award
Contact Us
Ritchlin Lab
601 Elmwood Ave/Box 695
Rochester, NY 14642
(585) 442-3214